Overview

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Status:
Recruiting
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University
Treatments:
Apatinib
Vinblastine
Vinorelbine